These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 11006018

  • 1. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I.
    Cell Immunol; 2000 Aug 25; 204(1):55-63. PubMed ID: 11006018
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 25; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 3. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y.
    Cancer Res; 2008 Apr 01; 68(7):2400-8. PubMed ID: 18381448
    [Abstract] [Full Text] [Related]

  • 4. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
    Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B.
    Cancer Biother Radiopharm; 1997 Jun 01; 12(3):177-86. PubMed ID: 10851464
    [Abstract] [Full Text] [Related]

  • 5. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 7. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL.
    Clin Cancer Res; 1999 Dec 15; 5(12):4259-63. PubMed ID: 10632368
    [Abstract] [Full Text] [Related]

  • 8. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M.
    Haematologica; 2003 Sep 15; 88(9):1002-12. PubMed ID: 12969808
    [Abstract] [Full Text] [Related]

  • 9. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B.
    Cancer Lett; 2010 Aug 01; 294(1):66-73. PubMed ID: 20202740
    [Abstract] [Full Text] [Related]

  • 10. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T.
    Ann Oncol; 1998 May 01; 9(5):527-34. PubMed ID: 9653494
    [Abstract] [Full Text] [Related]

  • 11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 12. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 01; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 13. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.
    Cancer Res; 1995 Jun 15; 55(12):2627-34. PubMed ID: 7540106
    [Abstract] [Full Text] [Related]

  • 14. Rituximab: an insider's historical perspective.
    Grillo-López AJ.
    Semin Oncol; 2000 Dec 15; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [Abstract] [Full Text] [Related]

  • 15. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ, Scott AM.
    Cancer Immun; 2002 Oct 07; 2():13. PubMed ID: 12747758
    [Abstract] [Full Text] [Related]

  • 16. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.
    Cancer Immunol Immunother; 2002 Mar 07; 51(1):15-24. PubMed ID: 11845256
    [Abstract] [Full Text] [Related]

  • 17. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 18. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 May 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 19. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M, Gramatzki M.
    Cancer Res; 1998 Jul 15; 58(14):3051-8. PubMed ID: 9679970
    [Abstract] [Full Text] [Related]

  • 20. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.